About Vesigen Therapeutics
Vesigen Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2019 by Quan Lu. Vesigen Therapeutics has raised $28.5 million across 4 funding rounds from investors including ARE, HHS and Linden Lake Venture Capital. The company has 27 employees. Its chief executive, as recorded, is Paulash Mohsen. Its focus areas include Life Sciences, Drug Delivery and Extracellular Vesicles Based. Its legal entity is VESIGEN, INC. Its competitors include Capienda Biotech, NanoTx Therapeutics and Nano Red Biotech.
Company details
Non-viral delivery platform for intracellular therapeutics using ARMMs technology. It offers a wide range of payloads, including mRNA, shRNA, ribozymes, signaling proteins, enzymes, antibody fragments, and editing complexes Cas9, gRNA directly into the cytoplasm of target cells.
- Headquarters Cambridge, United States
- Employees 27
- Founders Quan Lu
- SectorsHealthcare
- Email••••••••
- Website vesigen.com
- Social LinkedIn X
- Legal Name Vesigen, Inc.
- Total Equity Funding$28.5M (USD)
in 4 rounds
- Latest Funding Round$28.5M (USD), Series A
Jul 2020
- InvestorsARE
& 4 more
- Employee Count27
Funding Insights of Vesigen Therapeutics
Vesigen Therapeutics has successfully raised a total of $28.5M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $28.5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.5M
- Total Rounds 4
- Last Round Series A — $28.5M
- First Round $112,478
(Sep 2019)
- Investors Count 5
All 4 funding rounds of Vesigen Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $28.5M | Series A | – | Morningside, Leaps by Bayer | |
| Sep 2019 | $1.4M | Grant | – | – | |
| Sep 2019 | $149,607 | Grant | – | – | |
| Sep 2019 | $112,478 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Vesigen Therapeutics
Vesigen Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, HHS and Linden Lake Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are focused on early-stage biotechnology firms. | lindenlakevc.com | |||
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany | ||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Vesigen Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vesigen Therapeutics
2 people are tracked at Vesigen Therapeutics (2 in leadership); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Paulash Mohsen | CEO | Leadership |
Quan Lu | Co-Founder | Leadership |
Complete people profiles for Vesigen Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vesigen Therapeutics
3 dated milestones of Vesigen Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Vesigen Therapeutics is founded.
- Funding First funding round of $112K.
- Funding Latest funding round, Series A, of $28.5M.
Competitors of Vesigen Therapeutics
Vesigen Therapeutics has 3 listed competitors in our database. They include Capienda Biotech, NanoTx Therapeutics and Nano Red Biotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| capienda.us | 2017 | Tucson, United States | Developer of drug delivery technology | |||
| nano-tx.com | 2014 | San Antonio, United States | Radioactive liposomes for glioblastoma treatment are developed. | |||
| nanoredbiotech.com | 2015 | Milwaukee, United States | IR-activated liposome-based drug delivery technologies are developed. |
Detailed competitors of Vesigen Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Vesigen Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vesigen Therapeutics
Complete news archive for Vesigen Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vesigen Therapeutics
Vesigen Therapeutics was founded in 2019.
Vesigen Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Paulash Mohsen is the CEO of Vesigen Therapeutics, as recorded in our data.
Vesigen Therapeutics is a funded company, having raised a total of $28.5M across 4 funding rounds to date. The company's 1st funding round was a Grant of $112.48K, raised on Sep 2019.
Vesigen Therapeutics has 27 employees.
Non-viral delivery platform for intracellular therapeutics using ARMMs technology. It offers a wide range of payloads, including mRNA, shRNA, ribozymes, signaling proteins, enzymes, antibody fragments, and editing complexes Cas9, gRNA directly into the cytoplasm of target cells.
Vesigen Therapeutics's top competitors include NanoTx Therapeutics, Nano Red Biotech and Capienda Biotech.
Vesigen Therapeutics has 5 investors. Key investors include ARE, HHS, Linden Lake Venture Capital, Morningside, and Leaps by Bayer.
Vesigen Therapeutics operates through Vesigen, Inc..